DAMORA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
DAMORA THERAPEUTICS, INC. (DMRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 91.10 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 76.96K shares.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 14.14K shares, a 30.65% decline year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 20.39K shares, a 85.78% decline from fiscal 2024.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 143.42K shares, a 339.71% increase from fiscal 2023.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 32.62K shares, a 31.47% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 47.59K shares, a 72.12% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 76.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 91.10K shares 10-Q · filed 2026-08-10 | 91.10K shares derived: sum of 3 quarters · filed 2026-08-10 | 91.10K shares derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | 14.14K shares 10-Q · filed 2026-05-12 | 14.14K shares derived: sum of 2 quarters · filed 2026-05-12 | 14.14K shares derived: sum of 3 quarters · filed 2026-05-12 | 14.14K shares derived: sum of 4 quarters · filed 2026-05-12 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-19 | 0.00 shares derived: sum of 3 quarters · filed 2026-03-19 | 20.39K shares 10-K · filed 2026-03-19 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-06 | 20.39K shares 10-Q · filed 2025-11-06 | 66.21K shares derived: sum of 4 quarters · filed 2026-03-19 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 20.39K shares 10-Q · filed 2025-08-05 | 66.21K shares derived: sum of 3 quarters · filed 2026-03-19 | -1.28M shares derived: sum of 4 quarters · filed 2026-03-19 | |
| 2025-03-31 | 20.39K shares 10-Q · filed 2025-05-08 | 66.21K shares derived: sum of 2 quarters · filed 2026-03-19 | -1.28M shares derived: sum of 3 quarters · filed 2026-03-19 | -728.12K shares derived: sum of 4 quarters · filed 2026-03-19 | |
| 2024-12-31 | 45.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -1.30M shares derived: sum of 2 quarters · filed 2026-03-19 | -748.51K shares derived: sum of 3 quarters · filed 2026-03-19 | 143.42K shares 10-K · filed 2026-03-19 | |
| 2024-09-30 | -1.34M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | -794.33K shares derived: sum of 2 quarters · filed 2024-11-01 | 97.59K shares 10-Q · filed 2024-11-01 | -271.77K shares derived: sum of 4 quarters · filed 2025-03-19 | |
| 2024-06-30 | 547.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 1.44M shares 10-Q · filed 2024-08-12 | 1.07M shares derived: sum of 3 quarters · filed 2025-03-19 | 1.44M shares derived: sum of 4 quarters · filed 2025-03-19 | |
| 2024-03-31 | 891.92K shares 10-Q · filed 2024-04-29 | 522.56K shares derived: sum of 2 quarters · filed 2025-03-19 | 893.02K shares derived: sum of 3 quarters · filed 2025-03-19 | 898.77K shares derived: sum of 4 quarters · filed 2025-03-19 | |
| 2023-12-31 | -369.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | 1.09K shares derived: sum of 2 quarters · filed 2025-03-19 | 6.85K shares derived: sum of 3 quarters · filed 2025-03-19 | 32.62K shares 10-K · filed 2025-03-19 | 815.35K shares 10-K · filed 2024-03-08 |
| 2023-09-30 | 370.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 376.21K shares derived: sum of 2 quarters · filed 2023-11-06 | 401.98K shares 10-Q · filed 2023-11-06 | 433.32K shares derived: sum of 4 quarters · filed 2024-03-08 | |
| 2023-06-30 | 5.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | 31.52K shares 10-Q · filed 2023-07-31 | 62.87K shares derived: sum of 3 quarters · filed 2024-03-08 | 65.78K shares derived: sum of 4 quarters · filed 2024-03-08 | |
| 2023-03-31 | 25.77K shares 10-Q · filed 2023-04-28 | 57.11K shares derived: sum of 2 quarters · filed 2024-03-08 | 60.02K shares derived: sum of 3 quarters · filed 2024-03-08 | ||
| 2022-12-31 | 31.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | 34.26K shares derived: sum of 2 quarters · filed 2024-03-08 | 47.59K shares 10-K · filed 2024-03-08 | ||
| 2022-09-30 | 2.92K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 16.25K shares 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | 13.33K shares 10-Q · filed 2022-07-29 | ||||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-09 | 170.68K shares 10-K · filed 2023-03-09 | ||
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 170.68K shares 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | 170.68K shares 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |